EMA Authorised: Bemrist Breezhaler (indacaterol;mometasone furoate) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorised Bemrist Breezhaler, a fixed-dose inhaler combining indacaterol and mometasone furoate, for asthma; the marketing authorization holder is Nova…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Bemrist Breezhaler (indacaterol; mometasone furoate)

Snippet

Status: Authorised. Therapeutic area: Asthma. MAH: Novartis Europharm Limited. Decision date: 07/10/2025